ABLi Therapeutics Boosts Leadership Team and Board
28 May 2025 //
GLOBENEWSWIRE
ABLi Details FDA EOP2 Meeting On Risvodetinib For Parkinson`s
21 May 2025 //
GLOBENEWSWIRE
ABLi Launches Focus on Developing to Tackle c-Abl Neuro Diseases
12 May 2025 //
GLOBENEWSWIRE